ESPR · Esperion Therapeutics, Inc.

Current Thesis

The momentum trade is dead a definitive take-private pins this stock to a cash number. On 2026-05-01 ARCHIMED (healthcare-specialist PE) agreed to acquire Esperion for $3.16/share cash plus one CVR (up to $100M aggregate, ~$0.39/share), a 58% premium to the 2026-04-30 close of ~$2.00, valuing equity at up to ~$1.1B fully diluted. Shares last printed ~$3.14 (2026-06-03) roughly 0.6% below the cash floor, with the CVR thrown in near-free. That is a fixed-income-shaped arbitrage spread to a Q3-2026 close, not narrative velocity. There is no parabolic leg to ride: the ceiling is $3.16 absent a topping bid. For a narrative-momentum book this is a pass / DEAD theme. The +335% Stocktwits flash flagged in May was deal-speculation noise with no follow-through, exactly as a closed-spread arb tape behaves.

Bull Case

• Deal is signed, board-unanimous, financing committed. Definitive agreement 2026-05-01; debt financing arranged via Pharmakon Advisors funds → low financing-failure risk (8-K, DEFA14A filed).
• Minimal antitrust friction. ARCHIMED is a financial sponsor with no competing cardiovascular franchise; HSR clearance is the base case. Market pricing the stock at/below cash implies >95% close probability.
• $40M bempedoic-acid milestone if 2027 US net sales clear $350M (interpolated $300–350M).
• Improving standalone numbers underpin the bid. Q1 2026 revenue $80.1M (+23% YoY; product $43.4M, collaboration $36.7M), net loss narrowed to $25.2M from $40.5M YoY (10-Q, ~2026-05).

Bear Case

• Capped upside is the whole story. Price is a step function at $3.16 the antithesis of an accelerating narrative. Nothing to compound; this book's edge does not exist here.
• CVR likely worth pennies. Bempedoic-acid US net sales annualize to ~$174M off Q1's $43.4M; clearing $350M by 2027 requires a near-double low probability, so the $40M tranche is a lottery ticket.
• Asymmetric break risk. A failed shareholder vote, regulatory block, or financing collapse reverts the stock toward the ~$2.00 pre-deal level: +0.6% upside vs ~-36% downside.
• Capital opportunity cost. A ~0.6%-to-cash spread over ~one quarter is a bond return; an accelerating-narrative regime deploys that capital into names with an actual leg.

Setup & Price Structure

• One-day deal gap from ~$2.00 to ~$3.16 on 2026-05-01; tape has been flat-to-pinned since, last ~$3.14 (2026-06-03).
• 52-week range $0.915–$4.175; market cap ~$807M; P/E -30.34 (still pre-profit). The $4.175 high predates the deal cap.
• Moving averages, and EMA structure are non-informative price tracks deal-close probability, not trend. Post-deal volume contracted hard (the 0.25x ratio noted in May is normal for a closed arb).
• No clean momentum entry exists; there is no higher-low base, only the $3.16 ceiling and a thin spread beneath it.

Catalyst Calendar (next 30 days)

• ~late June 2026 (est.): DEFM14A definitive proxy + special-meeting date set (PREM14A already filed, ~2026-05).
• ~Q2–Q3 2026 (est.): HSR antitrust waiting-period expiry.
• ~July 2026 (est.): special-meeting shareholder vote on the ARCHIMED merger.
• ~early Aug 2026 (est.): Q2 2026 earnings largely moot given the pending close.
• Q3 2026: expected deal close, then Nasdaq delisting / privatization.

What Would Change Our Mind

• A daily close above $3.16 = competing/topping-bid signal → re-opens genuine upside and would flip this from pass to live (low probability given a PE buyer plus CVR structure).
• A deal break (vote fails, regulatory block, financing falls through) → stock craters toward ~$2.00; only then does the standalone NEXLETOL/NEXLIZET growth + ENBUMYST launch story merit a fresh momentum re-evaluation.
• Until one of those prints, the read stays pass a fully-priced arb is not this playbook's trade.

Correlation Notes

• Now a deal-idiosyncratic instrument: decoupled from XBI/biotech beta, cardiovascular peers, and broad risk-on/off. It trades on close probability, not sector flow or narrative.
• CVR value tracks NEXLETOL/NEXLIZET script trends and the ENBUMYST launch curve, not market regime.
• Pre-deal the name traded with the "biotech-precision-therapeutics" theme that theme is DEAD for ESPR while the merger stands.